Yan Xu

Yan Xu

Auto-generated profile, based on publicly available information

Yan Xu

American Association for Cancer Research

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
ACAndrew E Clark
Andrew E Clark
ZWZhaohui Wang
Zhaohui Wang
EOEmily Ostman
Emily Ostman
HZHui Zheng
Hui Zheng
HYHuiyu Yao
Huiyu Yao
JSJeffrey SoRelle
Jeffrey SoRelle
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge, and effective tracking requires rapid return of results. Surveillance of variants is typically performed by whole genome sequencing (WGS), which can be financially prohibitive and requires specialized equipment and bioinformatic expertise. Genotyping approaches are rapid methods for monitoring SARS-CoV-2 variants but require continuous adaptation. Fragment analysis may represent an approach for improved SARS-CoV-2 variant detection. Methods: A multiplex fragment analysis approach (CoVarScan) was validated using PCR targeting variants by size and fluorescent color. Eight SARS-CoV-2 mutational hot spots in variants of concern (VOCs) were targeted. Three primer pairs (recurrently deleted region [RDR] 1, RDR2, and RDR3–4) flank RDRs in the S-gene. Three allele-specific primers target recurrent spike receptor binding domain mutants. Lastly, 2 primer pairs target recurrent deletions or insertions in ORF1A and ORF8. Fragments were resolved and analyzed by capillary electrophoresis (ABI 3730XL), and mutational signatures were compared to WGS results. Results: We validated CoVarScan using 3544 clinical respiratory specimens. The assay exhibited 96% sensitivity and 99% specificity compared to WGS. The limit of detection for the core targets (RDR1, RDR2, and ORF1A) was 5 copies/reaction. Variants were identified in 95% of samples with cycle threshold (CT) <30 and 75% of samples with a CT 34 to 35. Assay design was frozen April 2021, but all subsequent VOCs have been detected including Delta (n = 2820), Mu, (n = 6), Lambda (n = 6), and Omicron (n = 309). Genotyping results are available in as little as 4 h. Conclusions: Multiplex fragment analysis is adaptable and rapid and has similar accuracy to WGS to classify SARS-CoV-2 variants.

1 November 2009 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KHKoc-Kan Ho
Koc-Kan Ho
JBJames R. Beasley
James R. Beasley
LBLaura Belanger
Laura Belanger
BBBlack Black
Black Black
JCJui-Hsiang Chan
Jui-Hsiang Chan
MWMaria Webb
Maria Webb

28 June 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SWShengwei Wu
Shengwei Wu
YZYufang Zhou
Yufang Zhou
ZXZhengzheng Xuan
Zhengzheng Xuan
LXLinghui Xiong
Linghui Xiong
XGXinyu Ge
Xinyu Ge
LYLin Yu
Lin Yu
There is a large amount of evidence that selective serotonin reuptake inhibitors (SSRIs) are related to cardiovascular toxicity, which has aroused concern regarding their safety. However, few studies have evaluated the effects of SSRIs on cardiac injury biomarkers, such as creatine kinase (CK) and creatine kinase isoenzyme (CK-MB). The purpose of our study was to determine whether SSRIs elevated CK and CK-MB levels of prior medicated depressive patients (PMDP) compared to first-episode drug-naïve depressive patients (FDDPs). We performed an observational and retrospective study involving 128 patients with major depressive disorder. Patients who had never used any type of antidepressant were designated FDDP; patients who had used only one type of SSRI but were not treated after a recent relapse were designated PMDP. Serum CK and CK-MB levels were measured before and after using SSRIs for a period of time. The duration of current treatment in the FDDP and PMDP groups was 16.200 ± 16.726 weeks and 15.618 ± 16.902 weeks, respectively. After SSRI treatment, levels of serum CK in the PMDP group were significantly higher than in the FDDP group. Univariate ANCOVA results revealed that PMDP was 22.313 times more likely to elevate CK (OR 22.313, 95% CI 9.605–35.022) and 2.615 times more likely to elevate CK-MB (OR 2.615, 95% CI 1.287–3.943) than FDDP. Multivariate ANCOVA revealed an interaction between the group and sex of CK and CK-MB. Further pairwise analysis of the interaction results showed that in female patients, the mean difference (MD) of CK and CK-MB in PMDP was significantly greater than that in FDDP (MD = 33.410, P = 0.000, 95% CI 15.935–50.886; MD = 4.613, P = 0.000, 95% CI 2.846–6.381). Our findings suggest that patients, especially females, who had previously used SSRI antidepressants were more likely to have elevated CK and CK-MB, indicators of myocardial muscle injury. Use of SSRIs should not be assumed to be completely safe and without any cardiovascular risks.

1 January 2018 in Neoplasma
Verified
Journal Article
Open access
YXY. Xu
Y. Xu
WWW. Wang
W. Wang
LLL. Li
L. Li
JLJ. Liu
J. Liu
XWX. Wu
X. Wu
RZR. Zhang
R. Zhang
FOXA1 and CK7 expression in esophageal squamous cell carcinoma and its prognostic significance

25 October 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LQLin Qiao
Lin Qiao
CDChuiwen Deng
Chuiwen Deng
QWQian Wang
Qian Wang
WZWen Zhang
Wen Zhang
YFYunyun Fei
Yunyun Fei
YLYongzhe Li
Yongzhe Li
Background: Neuromyelitis optica spectrum disorder (NMOSD) is a neurological complication of primary Sjögren's syndrome (pSS). Objective: We aimed to explore potential serological differences between pSS patients with and without NMOSD. Methods: There were 4 pSS patients with NMOSD and 8 pSS patients without NMOSD enrolled as the screening group for two-dimensional difference gel electrophoresis (DIGE) analysis. Then differential expressed protein spots between groups were identified by MALDI-TOF/TOF MS. The levels of the identified potential biomarkers were verified by ELISA in a second independent cohort including 22 pSS patients with NMOSD, 26 pSS without NMOSD and 30 NMOSD patients. Results: Nine proteins were identified significantly differently expressed (more than 1.5-fold, p < 0.05) between these two groups. Serum levels of clusterin and complement factor H (CFH) were further verified by ELISA. Results showed that the serum clusterin was significantly higher in NMOSD with pSS than without (298.33 ± 184.52 vs. 173.49 ± 63.03 ng/ml, p < 0.01), while the levels of CFH were lower in pSS patients with NMOSD than without (24.19 ± 1.79 vs. 25.87 ± 3.98 ng/ml, p < 0.01). Conclusion: This is the first study of serological comparative proteomics between pSS patients with and without NMOSD. Serum clusterin and CFH might be potential biomarkers for pSS patients with NMOSD and play important role in the pathogenesis of the disease but needs further verification.

1 January 2013 in International Journal of Biological Sciences
Verified
Journal Article
Open access
BBBihui Bao
Bihui Bao
YWYu Wang
Yu Wang
HHHua Hu
Hua Hu
HYHong Yao
Hong Yao
YLYuyan Li
Yuyan Li
ZLZhiqing Liang
Zhiqing Liang
Objective: To investigate the incidence of aneuploidy in fetuses with congenital heart defects (CHDs) and to further identify submicroscopic changes and global DNA methylation levels as potential biomarkers in complex CHD cases.